FIELD: medicine.
SUBSTANCE: group of inventions includes a compound of formula (I), or a pharmaceutically acceptable salt thereof, a stereoisomer, a pharmaceutical composition and the use of a compound of formula (I) for the preparation of a medicinal product. In formula (I), M1, M2, M4, M5 and M6 are each independently selected from C(R1) and N; M3 and M7 are C; X1, X2, X3 and L1, if present, are each independently selected from -C(R5)(R6)-, -N(R4)- and -O; ring A is selected from phenyl, pyridinyl, pyrimidinyl and pyridazinyl; cycle B is absent, X2 and X3 are directly connected by a chemical bond; R1, R2, R3, R5 and R6, if present, are each independently selected from hydrogen, halogen and the following groups, optionally substituted with one to three Q1: C1-6alkyl, -ORa; Q1, if present, is halogen; R4, if present, is independently selected from hydrogen and C1-6 alkyl; or X1 together with L1 forms pyrrolidinyl; Ra, when present, is selected from C1-6 alkyl, haloC1-6 alkyl; m, n, p, q, and t are each independently selected from either 0, 1, 2, 3, 4, or 5.
EFFECT: compound of formula (I) with inhibitory activity against TRK and/or ROS1 tyrosine kinases.
19 cl, 10 tbl, 7 ex
Authors
Dates
2023-06-19—Published
2019-11-08—Filed